DSIP

    Delta sleep-inducing peptide — sleep architecture

    5mg650.000 ₫

    Delivery method:

    Single vial

    650.000 ₫

    DSIP pen

    845.000 ₫

    Needs cold shipping

    DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid neuropeptide first isolated from the cerebral venous blood of sleeping rabbits. It is the only peptide named for and characterised by a direct effect on slow-wave (delta) sleep architecture in published human work — no other peptide in the category has equivalent EEG-validated delta-wave evidence. Researched outcomes include increased slow-wave sleep, improved sleep continuity, normalised cortisol rhythm, and improved stress-resilience and recovery markers. Unlike sedative GABAergics it does not suppress REM or compress slow-wave sleep; it deepens what is already there. Most commonly dosed pre-bed in short cycles to avoid tolerance. A core component of the Sleep stack alongside Epithalon, which re-sets the pineal–melatonin clock that schedules the deeper sleep DSIP enables.

    Dosage

    Typical research dose: 100–300 mcg subcutaneously, 30–60 min before bed, in 5–10 day cycles.

    Duration of effect

    Short plasma half-life; sleep effects observed across the night

    See full half-life table →

    Key Features

    • Delta-wave sleep modulation
    • Pre-bed cyclical dosing
    • Stress & circadian support
    • 5mg vial
    Contact Us

    Includes key details, half-life data, usage notes and research sources.

    Usage Instructions

    Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.

    Research Highlights

    • Backed by scientific research
    • Manufactured to pharmaceutical standards
    • Used in clinical research settings
    • Established safety profile

    Safety Information

    • •Consult your healthcare provider before use
    • •Not intended for pregnant or nursing women
    • •Store properly according to instructions
    • •Report any adverse effects to your healthcare provider

    Source: Kovalzon & Strekalova, PNAS (PMC, 1979)

    Clinical Research

    Delta sleep-inducing peptide produces a significant increase in slow-wave (delta) sleep and is associated with sleep-related growth hormone release — the foundational evidence that the peptide directly modulates deep-sleep architecture rather than acting as a generic sedative.

    Read full study

    Additional Research

    Source: Khudoerkov et al., Molecules (PMC, 2021)

    DSIP demonstrates measurable neuroprotective and motor-recovery effects after focal cerebral ischaemia — supporting its broader role as a stress-buffering and CNS-recovery peptide beyond sleep architecture alone.

    Read full study

    Human Clinical Trials

    • DSIP in chronic insomniaNeuropsychobiology · 1981

      Double-blind placebo-controlled crossover study in insomnia patients; clinical benefit was modest and inconsistent.

      Small, old study with weak results.

      Read the trial
      16
      participants
    See the full trial library